Clinical Medicine Reviews in Therapeutics

A Review of Pregabalin for the Treatment of Peripheral and Central Neuropathic Pain and Its Place in the Treatment of Chronic Pain

Submit a Paper

Clinical Medicine Reviews in Therapeutics 2011:3 325-346


Published on 19 Sep 2011

DOI: 10.4137/CMRT.S7398

Further metadata provided in PDF

Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Therapeutics


Pregabalin is an alpha2-gamma ligand indicated for the treatment of peripheral and central neuropathic pain. In this article, we will review the pharmacodynamics, pharmacokinetics, randomized clinical trials supporting its efficacy for a wide array of neuropathic painful conditions, and the tolerability of this medication. We will comment the main differences with gabapentin, its parent compound, both from the pharmacological and clinical perspective. Our experience in the clinical practice setting with pregabalin, its use in patients with refractory neuropathic pain and its rational use in combination regimens will also be reviewed. With all this information in mind, the place of pregabalin in the pharmacotherapy of neuropathic pain is explored, mainly through the review of recent clinical guidelines which, in fact, place pregabalin among the first-line treatments for the management of most neuropathic painful conditions.



BibTex citation   (BIBDESK, LATEX)

What Your Colleagues Say About Libertas Academica
This was the most efficient and user-friendly publishing process I have experienced.  The editorial team at Libertas Academica was phenomenal.  They kept me engaged with each step of the publishing process and they were timely and professional with their response to my inquiries.  I look forward to publishing additional articles with Libertas Academica in the future.
Dr Kevin Bain (PharmD, MPH, BCPS, CGP, CPH, FASCP, Philadelphia, PA, USA)
More Testimonials

Quick Links

New article and journal news notification services